Allyx Therapeutics

Overview

Pioneering a Synapse Protecting Oral Therapy. Our Mission.

Funding and backers

Total raised
$27.9M
4 rounds on record
Latest round
$27.9M
Venture round · May 2026 · 6 mo ago
Team
51-200
employees, estimated range
Grants
$5.8M
3 grants · CORDIS
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 4 Raised a round Venture round $27.9M · SEC Form D Sep 20, 2024 Won a grant $3.3M · CORDIS Sep 1, 2022 Won a grant $2M · CORDIS Sep 17, 2020 Won a grant $450k · CORDIS
Funding rounds
RoundDateAmountInvestorsSource
Venture round May 2026 $27.9M — SEC Form D
Grant Sep 2024 $3.3M — CORDIS
Grant Sep 2022 $2M — CORDIS
Grant Sep 2020 $450k — CORDIS
Registers and programsofficial lists and records that name the company
Legal entity Allyx Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Stephen BlochExecutive Officer, DirectorSEC Form D
Timothy SiegertExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Altay Therapeutics, Bristle
Index Ventures
backs Ankar
NEA
backs Orbis Medicines
Initialized Capital
backs Bristle
Daphni
backs Ankar
Norrsken
backs Ankar
Similar startupsby what they do, their industry and backers
SyntisVenture round $25M · 16 mo ago · Founded 2022 · 51-200 employees
Syntis Bio is unlocking the full therapeutic potential of the small intestine. Revolutionizing oral therapy for obesity, rare diseases, &…
Orbis MedicinesSeries A $97.2M · 22 mo ago · 51-200 employees · 1 role
Oral biologics, solved with intelligent chemistry. Powered by nGen, our discovery platform, we are pioneering a new modality: nCycle based…
Barricade TherapeuticsConvertible Note $100k · 5 mo ago · Founded 2017 · 51-200 employees
A New Era in Colorectal Cancer Therapy. Backed by over $17M in non-dilutive funding, Barricade is advancing a first-in-class oral therapy…
Altay TherapeuticsSeries A $37M · this month · 51-200 employees
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
Vous êtes51-200 employees
Synapse Medicine helps healthcare providers and their patients optimize drug regimens along the entire care journey.
SevaroSeries B $39M · 13 mo ago · 51-200 employees · 1 role
Seamless and life-saving stroke care with Synapse AI, Sevaro's virtual neurology services & advanced human-AI integration.

Financials

Total raised
$33.7M
Latest round
Venture - Series Unknown
Funding rounds
4
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 $27.9M Details
Grant 2024 $3.3M Details
Grant 2022 $2M Details
Grant 2020 $450k Details

People

Stephen Bloch
Executive Officer, Director
SEC Form D
Timothy Siegert
Executive Officer
SEC Form D
Stephen Strittmatter
Director
SEC Form D
Paul Fonteyne
Director
SEC Form D
Gregory Ho
Director
SEC Form D
Robert Bettigole
Director
SEC Form D
Kevin Rakin
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New Haven United States
HQ
Corporate Headquarters
50-200 est. staff
555 Long Wharf Drive, Floor 11, New Haven, CT 06511
company site